CEP 1347
(Synonyms: KT7515) 目录号 : GC12841CEP 1347 是一种具有神经保护作用的 JNK/SAPK 通路抑制剂。
Cas No.:156177-65-0
Sample solution is provided at 25 µL, 10mM.
CEP-1347, also called KT 7515, is an inhibitor of the c-Jun N-terminal kinase (JNK) signaling pathway, with an IC50 value for JNK1 activation of 20 ± 2 nM in rat embryonic motoneurons [1].
The JNK pathway, also known as the stress-activated protein kinase (SAPK) pathway, is one of the signaling cascades that mediate the apoptotic death in response to a variety of stressful stimuli. JNK activation by phosphorylation is important for neuronal cell death after injury in vivo and after trophic factor withdrawal in vitro [2].
CEP-1347 induced neuronal survival. JNK1 activity in untreated cell cultures increased approximately fourfold within 24 hr after plating. As early as 15 min after the application of CEP-1347 at 500 nM, the activity of JNK1 sharply decreased to ~50% of control levels. For the next 24 hr, the activity of JNK1 continued to decrease. Cultures rich in motoneurons were grown in the presence of CEP-1347 at increasing concentrations, and the IC50 for JNK1 activity at 22 hr was 21 ± 2 nM, whereas the EC50 for cell survival at 5 d was 20 ± 2 nM [1].
CEP-1347 can affect noise-induced hearing loss. Data showed that hearing thresholds 2 d before noise exposure showed no significant difference between the noise-exposed control and treated group. Hearing threshold shifts in all guinea pigs 2 d after the noise exposure. By day 6 after exposure, threshold shifts were significantly less in the CEP-1347 group than in the noise-exposed control group. By 2 weeks after exposure, the difference between the two groups became more pronounced [2].
References:
[1]. Maroney AC, Glicksman MA, Basma AN, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway[J]. The Journal of neuroscience, 1998, 18(1): 104-111.
[2]. Pirvola U, Liang XQ, Virkkala J, et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation[J]. The Journal of Neuroscience, 2000, 20(1): 43-50.
Cas No. | 156177-65-0 | SDF | |
别名 | KT7515 | ||
化学名 | (5S,6S,8S)-methyl 2,11-bis((ethylthio)methyl)-5-methyl-13-oxo-6,7,8,13,14,15-hexahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacene-6-carboperoxoate | ||
Canonical SMILES | O=C([C@@H](C1)[C@]2(C)O[C@@H]1N3C4=C5N2C(C=CC(CSCC)=C6)=C6C5=C(CNC7=O)C7=C4C8=C3C=CC(CSCC)=C8)OOC | ||
分子式 | C33H33N3O5S2 | 分子量 | 615.76 |
溶解度 | <6.16mg/ml in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.624 mL | 8.12 mL | 16.2401 mL |
5 mM | 0.3248 mL | 1.624 mL | 3.248 mL |
10 mM | 0.1624 mL | 0.812 mL | 1.624 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet